Katharine R Owen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9087594/publications.pdf

Version: 2024-02-01

471509 454955 3,511 27 17 30 citations h-index g-index papers 30 30 30 9188 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The genetic architecture of type 2 diabetes. Nature, 2016, 536, 41-47.	27.8	952
2	An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. Diabetes, 2017, 66, 2888-2902.	0.6	615
3	Rare and low-frequency coding variants alter human adult height. Nature, 2017, 542, 186-190.	27.8	544
4	Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nature Genetics, 2015, 47, 1415-1425.	21.4	365
5	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	21.4	286
6	Assessment of High-Sensitivity C-Reactive Protein Levels as Diagnostic Discriminator of Maturity-Onset Diabetes of the Young Due to <i>HNF1A</i> Mutations. Diabetes Care, 2010, 33, 1919-1924.	8.6	103
7	Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution. Nature Genetics, 2019, 51, 452-469.	21.4	89
8	Genetics of type 2 diabetes. Current Opinion in Genetics and Development, 2007, 17, 239-244.	3.3	77
9	Logistic regression has similar performance to optimised machine learning algorithms in a clinical setting: application to the discrimination between type 1 and type 2 diabetes in young adults. Diagnostic and Prognostic Research, 2020, 4, 6.	1.8	69
10	Genetics of Monogenic Diabetes: Present Clinical Challenges. Current Diabetes Reports, 2018, 18, 141.	4.2	50
11	A Low-Frequency Inactivating <i>AKT2</i> Variant Enriched in the Finnish Population Is Associated With Fasting Insulin Levels and Type 2 Diabetes Risk. Diabetes, 2017, 66, 2019-2032.	0.6	47
12	Plasma Fucosylated Glycans and C-Reactive Protein as Biomarkers of HNF1A-MODY in Young Adult–Onset Nonautoimmune Diabetes. Diabetes Care, 2019, 42, 17-26.	8.6	44
13	Language matters. Addressing the use of language in the care of people with diabetes: position statement of the English Advisory Group. Diabetic Medicine, 2018, 35, 1630-1634.	2.3	36
14	Common Variation in the LMNA Gene (Encoding Lamin A/C) and Type 2 Diabetes: Association Analyses in 9,518 Subjects. Diabetes, 2007, 56, 879-883.	0.6	34
15	Sequence data and association statistics from 12,940 type 2 diabetes cases and controls. Scientific Data, 2017, 4, 170179.	5.3	31
16	Self-management of Diabetes in Children and Young Adults Using Technology and Smartphone Applications. Current Diabetes Reviews, 2014, 10, 298-301.	1.3	31
17	Monogenic diabetes in adults: what are the new developments?. Current Opinion in Genetics and Development, 2018, 50, 103-110.	3.3	28
18	When to consider a diagnosis of MODY at the presentation of diabetes: aetiology matters for correct management. British Journal of General Practice, 2016, 66, e457-e459.	1.4	19

#	Article	IF	CITATIONS
19	Maturity onset diabetes of the young due to HNF1A variants in Croatia. Biochemia Medica, 2018, 28, 020703.	2.7	17
20	The correlation between breath acetone and blood betahydroxybutyrate in individuals with type 1 diabetes. Journal of Breath Research, 2021, 15, 017101.	3.0	16
21	The clinical application of non-genetic biomarkers for differential diagnosis of monogenic diabetes. Diabetes Research and Clinical Practice, 2009, 86, S15-S21.	2.8	13
22	Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods. Glycoconjugate Journal, 2021, 38, 375-386.	2.7	10
23	Traditional clinical criteria outperform high-sensitivity C-reactive protein for the screening of hepatic nuclear factor 1 alpha maturity-onset diabetes of the young among young Asians with diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2018, 9, 271-282.	3.2	6
24	Altered cortisol metabolism in individuals with HNF1Aâ€MODY. Clinical Endocrinology, 2020, 93, 269-279.	2.4	4
25	Fucosylated AGP glycopeptides as biomarkers of HNF1A-Maturity onset diabetes of the young. Diabetes Research and Clinical Practice, 2022, 185, 109226.	2.8	4
26	Development of an exoglycosidase plate-based assay for detecting $\hat{l}\pm 1$ -3,4 fucosylation biomarker in individuals with HNF1A-MODY. Glycobiology, 2022, 32, 230-238.	2.5	3
27	Type 2 diabetes in the young: why we should worry. Practical Diabetes, 2014, 31, 225-227.	0.3	2